


Hormone Replacement Capsule Analysis by HPLC - AppNote

Separation of Estriol, Estradiol, & Progesterone

This gradient method features a separation of the three components of a hormone replacement formulation. *Figure A* shows a five run overlay of the formulation extract injections. *Figure B* shows a zoomed-in view so that the Estriol and Estradiol Peaks, which are present in much lower concentration than Progesterone, can be seen clearly. *Figure B* also shows separation of an impurity from the Progesterone Peak.



Peak:



2. Estradiol

3. Progesterone

Method Conditions

Column: Cogent UDC Cholesterol[™], 4μm, 100Å

Catalog No.: 69069-7.5P **Dimensions:** 4.6 x 75mm

Mobile Phase:

A: DI Water / 0.1% Formic Acid (v/v)
B: Acetonitrile / 0.1% Formic Acid (v/v)

Gradient:

Time (minutes)	%B
0	33
2	33
11	65
12	33

Post Time: 3 minutes

Flow rate: 1.0 mL / minute Detection: UV @ 210nm

Injection vol.: 1µL

Sample Preparation: The contents of a capsule containing 0.124 mg Estradiol, 1.001 mg Estriol, and 50 mg Progesterone were added to a 25 mL volumetric flask. The flask was diluted to mark with solvent B and sonicated 10 minutes. Then A portion was filtered with a 0.45 μ m Nylon Syringe Filter (MicroSolv Tech. Corp.). Peak identities were confirmed by individual standards of 0.1 mg / mL in a Solvent B diluent.



Attachment

No 175 Hormone Replacement Capsule Analysis pdf 0.4 Mb Download File

Printed from the Chrom Resource Center

MicroSolv Technology Corporation

9158 Industrial Blvd. NE, Leland, NC 28451 tel. (732) 380-8900, fax (910) 769-9435

Email: customers@mtc-usa.com

Website: www.mtc-usa.com

Date: 03-05-2024